In Depth 25 Apr 2017
How Biotech is Mastering Multiple Sclerosis: A Review
With last month’s FDA approval, Ocrevus (ocrelizumab), became the first drug for primary-progressive multiple sclerosis. Roche may be the first, but others in the biotech community are also working hard to bring their own therapeutics for the disease to market. Multiple sclerosis (MS) is an autoimmune disease that affects the nervous system, and around 2 […]